KLTO ANEW Medical: Enterprise Value to EBITDA Ratio
The business model of Klotho Neurosciences Inc (KLTO) relies on the study of the Klotho protein to slow neuronal aging and the protection of unique therapeutic methodologies. This chart illustrating share price dynamics through the lens of EV/EBITDA is 0.00. However, the company faces intense pressure from industry behemoths in the race for leadership in dementia treatment, while a lack of profitability necessitates a reliance on external investments and strict cash management.
Comprehensive metric breakdowns and analytics for anewmeds.com (KLTO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Klotho Neurosciences Inc|KLTO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Klotho Neurosciences|KLTO - Company Aggregate Debt|Debts to Book Capitalization KLTO|KLTO - Long-Term Debt|Company Current Liabilities Klotho Neurosciences|Quick Liquidity anewmeds.com
- financial results and valuation multiples details:
KLTO - Final Profit|Expected Profit Klotho Neurosciences Inc|KLTO - Market Cap to Earnings|Future Price to Earnings Klotho Neurosciences|KLTO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple KLTO|KLTO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Klotho Neurosciences|KLTO - Net earnings per share for the last four quarters|Quarterly EPS earnings growth anewmeds.com|KLTO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Klotho Neurosciences Inc
Fundamental company valuation:ANEW Medical, Inc. KLTO
This indicator compares the total enterprise value to its operating profit before depreciation and amortization, determining the market premium for cash flow generation regardless of debt load. By analyzing the EV/EBITDA multiple chart, an investor assesses the efficiency of capital expenditures by Klotho Neurosciences Inc (KLTO) in developing neurobiological therapies against aging and Parkinson's disease for expansion into the geriatric drug market.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC: Enterprise Value to EBITDA Ratio|axsome.com - Enterprise Value to Operating Income Before Depreciation Ratio|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|anavex.com (AVXL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|Total Company Value to Operating Income Before Depreciation Ratio neurogene.com (NGNE)|AC Immune SA - EV/EBITDA Multiple|Voyager Therapeutics Inc (VYGR) - Enterprise Value to EBITDA Ratio|NMRA: EV/EBITDA Multiple|SCLX - Total Company Value to Operating Income Before Depreciation Ratio|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Alpha Cognition Corp ACOG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|Inhibikase Therapeutics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAVA (Cassava)|ASRT - Enterprise Value to EBITDA Ratio|Coya - EV/EBITDA Multiple|Company Value to EBITDA Vistagen Therapeutics|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABOS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CRVO|ATHE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CLNN|Total Company Value to Operating Income Before Depreciation Ratio pepgen.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Grace Therapeutics, Inc. (GRCE) - Enterprise Value to EBITDA Ratio|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MTVA|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|Enterprise Value to Operating Income Before Depreciation Ratio HSDT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to EBITDA Ratio CYCN|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CHRO - EV/EBITDA Multiple|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITCI (Intra-Cellular Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio NRBO|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vigil Neuroscience|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com - Business Value to Operating Income Before Depreciation
